Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1298517

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1298517

Alzheimer's Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

PUBLISHED:
PAGES: 144 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 2499
PDF & Excel (5 User License)
USD 3499
PDF & Excel (Corporate License)
USD 4499

Add to Cart

The global alzheimer's drugs market size reached US$ 7.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.4 Billion by 2028, exhibiting a growth rate (CAGR) of 6.11% during 2023-2028.

Alzheimer's is a disease characterized by the degeneration of nerve cells in several areas of the brain. It causes loss of cognitive function, such as memory, language, thinking and behavior. The common symptoms of Alzheimer's include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning. It is usually diagnosed by performing physical exams, blood tests, brain imaging, and mental status and neuropsychological testing. According to the results, doctors prescribe different medications to alleviate symptoms. Alzheimer's drugs influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.

Alzheimer's Drugs Market Trends:

Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer's disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer's drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global alzheimer's drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Donepezil

Galantamine

Rivastigmine

Memantine

Others

Breakup by Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Stores

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited.

Key Questions Answered in This Report:

  • How has the global alzheimer's drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alzheimer's drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alzheimer's drugs market and who are the key players?
  • What is the degree of competition in the industry?
Product Code: SR112023A2695

Table of Contents

1   Preface

2   Scope and Methodology

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Alzheimer's Drugs Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Drug Class

  • 6.1  Donepezil
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Galantamine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3  Rivastigmine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4  Memantine
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5  Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7   Market Breakup by Distribution Channel

  • 7.1  Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3  Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4  Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8   Market Breakup by Region

  • 8.1  North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2  Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3  Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4  Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5  Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9   SWOT Analysis

  • 9.1  Overview
  • 9.2  Strengths
  • 9.3  Weaknesses
  • 9.4  Opportunities
  • 9.5  Threats

10  Value Chain Analysis

11  Porters Five Forces Analysis

  • 11.1  Overview
  • 11.2  Bargaining Power of Buyers
  • 11.3  Bargaining Power of Suppliers
  • 11.4  Degree of Competition
  • 11.5  Threat of New Entrants
  • 11.6  Threat of Substitutes

12  Price Analysis

13  Competitive Landscape

  • 13.1  Market Structure
  • 13.2  Key Players
  • 13.3  Profiles of Key Players
    • 13.3.1  Abbvie Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2  AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3  Biogen Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4  Daiichi Sankyo Company Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5  Eisai Co. Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6  Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7  H. Lundbeck A/S
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8  F. Hoffmann-La Roche AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 SWOT Analysis
    • 13.3.9  Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10  Novartis AG
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11  Ono Pharmaceutical Co. Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12  Pfizer Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13  Teva Pharmaceutical Industries Limited
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis
Product Code: SR112023A2695

List of Figures

  • Figure 1: Global: Alzheimer's Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Alzheimer's Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Alzheimer's Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 4: Global: Alzheimer's Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 5: Global: Alzheimer's Drugs Market: Breakup by Region (in %), 2022
  • Figure 6: Global: Alzheimer's Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 7: Global: Alzheimer's Drugs (Donepezil) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 8: Global: Alzheimer's Drugs (Donepezil) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 9: Global: Alzheimer's Drugs (Galantamine) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Alzheimer's Drugs (Galantamine) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Alzheimer's Drugs (Rivastigmine) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Alzheimer's Drugs (Rivastigmine) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Alzheimer's Drugs (Memantine) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Alzheimer's Drugs (Memantine) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Alzheimer's Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Alzheimer's Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Alzheimer's Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Alzheimer's Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Alzheimer's Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Alzheimer's Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Alzheimer's Drugs (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Alzheimer's Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Alzheimer's Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Alzheimer's Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: North America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: North America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: United States: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: United States: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Canada: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Canada: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Asia Pacific: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Asia Pacific: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: China: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: China: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Japan: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Japan: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: India: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: India: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: South Korea: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: South Korea: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Australia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Australia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Indonesia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Indonesia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Europe: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Europe: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Germany: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Germany: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: France: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: France: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: United Kingdom: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: United Kingdom: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Italy: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Italy: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Spain: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Spain: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Russia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Russia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Latin America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Latin America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Brazil: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Brazil: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Mexico: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Mexico: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Middle East and Africa: Alzheimer's Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Middle East and Africa: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Global: Alzheimer's Drugs Industry: SWOT Analysis
  • Figure 74: Global: Alzheimer's Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Alzheimer's Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alzheimer's Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Alzheimer's Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Alzheimer's Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 4: Global: Alzheimer's Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 5: Global: Alzheimer's Drugs Market: Competitive Structure
  • Table 6: Global: Alzheimer's Drugs Market: Key Players
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!